医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2015年
15期
52-53
,共2页
幽门螺旋杆菌%消化性溃疡%治疗%护理
幽門螺鏇桿菌%消化性潰瘍%治療%護理
유문라선간균%소화성궤양%치료%호리
Helicobacter pylori%Peptic ulcer%Treatment%Nursing
目的探讨分析幽门螺旋杆菌阳性消化性溃疡的治疗与护理。方法分析我院近两年收治的幽门螺旋杆菌阳性消化性溃疡病患180例,实验组病患采用埃索美拉唑、阿莫西林和左氧氟沙星联合治疗,对照组病患采用雷尼替丁进行治疗,比较两组病患的治疗有效率,以及不良症状消失的情况。结果实验组患者治疗有效率(92.22%)明显高于对照组患者(56.67%):同时实验组患者恶心、便秘或腹泻、腹痛以及其他不良症状消失率(95.56%)、(96.67%)、(93.33%)、(84.44%)明显高于对照组患者(68.89%)、(71.11%)、(66.67%)、(70.00%),<0.05,具有统计学意义。结论埃索美拉唑、阿莫西林以及氧氟沙星联合用于治疗幽门螺旋杆菌阳性消化性溃疡具有显著疗效。
目的探討分析幽門螺鏇桿菌暘性消化性潰瘍的治療與護理。方法分析我院近兩年收治的幽門螺鏇桿菌暘性消化性潰瘍病患180例,實驗組病患採用埃索美拉唑、阿莫西林和左氧氟沙星聯閤治療,對照組病患採用雷尼替丁進行治療,比較兩組病患的治療有效率,以及不良癥狀消失的情況。結果實驗組患者治療有效率(92.22%)明顯高于對照組患者(56.67%):同時實驗組患者噁心、便祕或腹瀉、腹痛以及其他不良癥狀消失率(95.56%)、(96.67%)、(93.33%)、(84.44%)明顯高于對照組患者(68.89%)、(71.11%)、(66.67%)、(70.00%),<0.05,具有統計學意義。結論埃索美拉唑、阿莫西林以及氧氟沙星聯閤用于治療幽門螺鏇桿菌暘性消化性潰瘍具有顯著療效。
목적탐토분석유문라선간균양성소화성궤양적치료여호리。방법분석아원근량년수치적유문라선간균양성소화성궤양병환180례,실험조병환채용애색미랍서、아막서림화좌양불사성연합치료,대조조병환채용뢰니체정진행치료,비교량조병환적치료유효솔,이급불량증상소실적정황。결과실험조환자치료유효솔(92.22%)명현고우대조조환자(56.67%):동시실험조환자악심、편비혹복사、복통이급기타불량증상소실솔(95.56%)、(96.67%)、(93.33%)、(84.44%)명현고우대조조환자(68.89%)、(71.11%)、(66.67%)、(70.00%),<0.05,구유통계학의의。결론애색미랍서、아막서림이급양불사성연합용우치료유문라선간균양성소화성궤양구유현저료효。
Objective To explore the analysis treatment and care of H.pylori-positive peptic ulcer.Methods Analysis of H.pylori-positive peptic ulcer patients admit ed to our hospital in the past two years,180 cases,the experimental group patients using esomeprazole,amoxicil in and levofloxacin combination therapy,the control group of patients treated using ranitidine,to compare the treatment ef iciency and symptoms of adverse situations of two groups patients.Results Ef ective treatment of patients in the experimental group (92.22%)was significantly higher in patients (56.67%);while the experimental group were nausea,constipation or diarrhea,abdominal pain and other adverse symptoms disappearance rate (95.56%), (96.67%), (93.33%), (84.44%)was significantly higher in patients (68.89%),(71.11%),(66.67%),(70.00%), <0.05,statistical y significant.Conclusion Esomeprazole,amoxicil in and levofloxacin combined for the treatment of Helicobacter pylori-positive peptic ulcer disease has a significant ef ect,be worthy of clinical promotion.